our therapy - Novocure

about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy

mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.

delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.

treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
patient-forward
news and media

media gallery

Featured Stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

19.80

0.50

last update 8/16/2017 1:22PM
careers

working with us

our locations

current job listings

mechanism of action

Tumor Treating Fields, or TTFields, are low intensity, alternating electric fields that disrupt cell division through physical interactions with key molecules during mitosis in solid tumor cancers.

cancer cell

structures align within the cell

electric fields interfere with cell division

cell death

delivery method

Click the link below to discover our Tumor Treating Fields delivery system.

LEARN MORE

treating cancer with electric fields

There are two well-established physical processes that TTFields use to disrupt dividing cells, dipole alignment and dielectrophoresis.

Watch Video

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy
- mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.
- delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.
- treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
patient-forward
news and media
- media gallery
- Featured Stories
investor relations
careers